Usefulness of the CLLflow score. Issue 6 (19th January 2018)

• Record Type: Journal Article
• Authors: Sorigue, Marc; Franch‐Sarto, Mireia; Sarrate, Edurne; Junca, Jordi
• Is Part Of: Cytometry. Volume 94:Issue 6(2018)
• Page Start: 950
• Page End: 952
• Publication Date: 2018-01-19
• Subjects: CD200 -- chronic lymphocytic leukemia -- B‐cell lymphoproliferative disorder -- CD79b -- Moreau CLL score; Flow cytometry -- Diagnostic use -- Periodicals; Cytodiagnosis -- Periodicals; 616.07582
• DOI: 10.1002/cyto.b.21623
• Languages: English
• ISSNs: 1552-4949

Abstract

Abstract : Background: The CLLflow score was recently suggested as an improvement over the Moreau score (MS) for the diagnosis and classification of B‐cell lymphoproliferative disorders (B‐LPD). Methods: We determined the CLLflow score in peripheral blood or bone marrow of a series of cases with an inconclusive immunophenotype, including samples with a MS of 3 ( n = 52) and CD5‐positive with a score of 2 ( n = 38). As controls, B‐LPD with a MS of 0–1 ( n = 95), CD5‐negative score 2 ( n = 24), and score 4–5 (i.e., chronic lymphocytic leukemia [CLL], n = 166) were included. Results: The CLLflow score was positive (suggestive of CLL) in all CLL cases and negative in all MS <2, regardless of CD200‐positivity, which occurred in 31% (29/95) of cases. The CLLflow score was positive in 71%, 29%, and 8% of samples with a MS 3, CD5‐positive score 2, and CD5‐negative score 2, respectively. Discussion: Our results suggest that the CLLflow is useful in the differential diagnosis of cases with inconclusive immunophenotype. © 2018 International Clinical Cytometry Society